Tuesday, February 04, 2020 11:49:36 AM
One of my early posts elsewhere after buying Cytodyn stock. I've always wanted to see the data for virus levels across the entire 5 year span to see if the below 1 virus levels occurred near the end of that time span.
[/quote]CD4+ memory T-cells (where hidden HIV reservoirs hide) differentiate themselves after the naive CD4+ T-cells are already produced and in response to an event. As long as there are any CD4+ cells with active CCR5 receptors than CCR5 specific HIV can reproduce when the hidden reservoirs of HIV activate.
With CD32 T-cells there are no CCR5 receptors. With bone marrow transplants chemo will destroy the existing blood producing cells so any replacement with CD32 variant will only produce non-CCR5 expressive T-cells. There will be no place for HIV to latch on and replicate.
Since the reservoirs exist outside of the marrow a non-CD32 transplant will not stop HIV.
Best case scenario - The half life of CD4+ memory T-cells is 44 months. Without a virological event leronlimab may be able to block all CCR5 receptors, keeping new CD4+ memory T-cells from becoming infected. So every 44 months, under best conditions, half the reservoir ceases to exist. Over a very long period of time leronlimab may effectuate a cure.
ohm20 5/17/2019[/quote]
[/quote]CD4+ memory T-cells (where hidden HIV reservoirs hide) differentiate themselves after the naive CD4+ T-cells are already produced and in response to an event. As long as there are any CD4+ cells with active CCR5 receptors than CCR5 specific HIV can reproduce when the hidden reservoirs of HIV activate.
With CD32 T-cells there are no CCR5 receptors. With bone marrow transplants chemo will destroy the existing blood producing cells so any replacement with CD32 variant will only produce non-CCR5 expressive T-cells. There will be no place for HIV to latch on and replicate.
Since the reservoirs exist outside of the marrow a non-CD32 transplant will not stop HIV.
Best case scenario - The half life of CD4+ memory T-cells is 44 months. Without a virological event leronlimab may be able to block all CCR5 receptors, keeping new CD4+ memory T-cells from becoming infected. So every 44 months, under best conditions, half the reservoir ceases to exist. Over a very long period of time leronlimab may effectuate a cure.
ohm20 5/17/2019[/quote]
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
